Dermatitis Research Review Issue 19 with commentary by Associate Professor John Frew.
This review is a unique Australian publication providing topical, relevant and accessible information for health professionals with an interest in Dermatitis. In essence, the review is a summary of what we consider to be some of the most significant new studies in this area.
Details
In this edition we feature:
- Risk of concomitant skin, GI and ocular EBDs with seborrheic dermatitis
- Tralokinumab safe and tolerable long-term
- Pumecitinib gel safe and efficacious for mild-to-moderate AD
- Paediatric AD linked to higher maternal depression scores
- Canadian recommendations for the management of patients with systemic-eligible AD
- Sleep disturbances linked to anxiety and depression in adolescents with AD
- Patient preferences in the benefit–risk assessment of treatments in China
- Topical tapinarof 1% cream is effective and safe
- Proactive vs reactive maintenance after dupilumab discontinuation
- Amlitelimab promising for hard-to-treat head and neck AD.
To access this publication please click ‘Enrol Now’ and you’ll be directed to the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review –
trish@researchreview.com.au
This activity is accepted by CPD Home as Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide.
Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.
